ImmuNews is designed to educate and inform our shareholders and followers of happenings in the rapidly developing field of cancer immunotherapy - Thanks for supporting our efforts to develop a new industry focused on Immunotherapy treatments for cancer.
New York, NY (PRWEB) July 31, 2012
immunovative, Inc. (“IMUN”) (OTCBB: IMUN) announces today that ImmuNews, a newsletter published by Immunovative, Inc. is now available to the public. ImmuNews is designed to educate and inform our shareholders and followers of happenings in the rapidly developing field of cancer immunotherapy and provide updated information on our progress toward bringing our own products to the market. We will feature each month selected news stories and published research in the field of cancer immunotherapy for expert commentary, including an analysis of how the selected news and/or results impact our current and future product development efforts.
You may subscribe to our Newsletter by visiting http://www.imun.com or http://www.imun.us - You may view our Newsletter by visiting us on Facebook.com/Immunovative – To view or learn more about our Company you may also visit us on Youtube.com/Immunovativenews
About Immunovative, Inc.:
On December 15, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN’s website at http://www.imun.com
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative Therapies Ltd specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at: http://www.immunovative.co.il
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.